// App-Quantinova.ai

2229 : A panel of NSCLC patient derived xenografts displays a distinct sensitivity profile towards checkpoint inhibitor treatment in vitro and in vivo

Researchers

Presenter

  • Robert Nunan

Principal Investigators

  • Eva Oswald

  • Ilona Aylott

  • Friedrich Feuerhake

  • Rhiannon Jenkinson

  • Julia Schler

Medical Centers

  • Charles River Laboratories, Portishead, UK

  • Charles River Laboratories, Freiburg, Germany.

  • Medical Center Hannover, Freiburg, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • C-X3-C Motif Chemokine Ligand 1

  • Granulocyte-macrophage-colony stimulating factor

  • Interleukin 4

  • Tripartite motif containing 27

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • GM-CSF

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved